Vanderbilt Eye Institute researchers have discovered that an imbalance in the ionic environment of retinal ganglion cells may contribute to functional impairments in glaucoma.

Understanding details of how arrestins deactivate signaling by G-protein coupled receptors is key to the design of new therapeutics aimed at these cellular "inboxes" that are targeted by up to half of all pharmaceuticals.

Increasing a certain signaling molecule prevents the degeneration of retinal cells that are lost in glaucoma, suggesting a new way to treat this disease.

The modular architecture of small heat-shock proteins contributes to the ability of these proteins to aid cells in responding to stress.

New findings highlight microRNAs — molecules that regulate gene expression — that are differentially expressed in glaucoma and could be candidate biomarkers or targets for therapy.

Studies of alpha-B crystallin in zebrafish could ultimately lead to improved treatment for cataracts and heart disease.

A signaling molecule called interleukin-6 may be a therapeutic target to prevent vision loss or nerve degeneration in glaucoma, Vanderbilt researchers have discovered.